Al Jefri A H, Abujazar H, Al-Ahmari A, Al Rawas A, Al Zahrani Z, Alhejazi A, Bekadja M A, Ibrahim A, Lahoucine M, Ousia S, Bazarbachi A
Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Bone Marrow Transplant Program, King Hussein Cancer Center, Amman, Jordan.
Bone Marrow Transplant. 2017 Apr;52(4):588-591. doi: 10.1038/bmt.2016.300. Epub 2016 Nov 28.
Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) of the liver is a serious, early complication of haematopoietic stem cell transplantation (HSCT), severe and very severe forms of which are associated with a high mortality rate. A wide variety of patient, disease and treatment-related risk factors for VOD/SOS have been identified. Several bodies have published recommendations for the diagnosis, prevention and management of VOD/SOS following HSCT. A group of regional experts have developed a consensus statement on the diagnosis, prevention and management of VOD/SOS in the Middle East and North Africa region to help in the management of HSCT patients in the region. Risk factors of particular relevance in the region include iron overload in thalassaemia patients, some hereditary metabolic disorders due to consanguinity and infection with hepatitis virus B or C. Recommendations include diagnosis of VOD/SOS based on established clinical criteria, prophylaxis with defibrotide and/or ursodeoxycholic acid in patients at increased risk of VOD/SOS, and treatment with defibrotide for patients with severe/very severe VOD/SOS (and, if clinically indicated, in those with moderate or rapidly progressing VOD/SOS, as per the new European Society for Blood and Marrow Transplantation classification).
肝静脉闭塞病/肝窦阻塞综合征(VOD/SOS)是造血干细胞移植(HSCT)严重的早期并发症,其严重和极严重形式与高死亡率相关。已确定了多种与患者、疾病及治疗相关的VOD/SOS风险因素。多个机构已发布HSCT后VOD/SOS诊断、预防及管理的建议。一组地区专家就中东和北非地区VOD/SOS的诊断、预防及管理制定了共识声明,以协助该地区HSCT患者的管理。该地区特别相关的风险因素包括地中海贫血患者的铁过载、近亲结婚导致的一些遗传性代谢紊乱以及乙型或丙型肝炎病毒感染。建议包括根据既定临床标准诊断VOD/SOS,对VOD/SOS风险增加的患者使用去纤苷和/或熊去氧胆酸进行预防,对重度/极重度VOD/SOS患者(以及根据欧洲血液和骨髓移植学会新分类,临床指征明确的中度或快速进展VOD/SOS患者)使用去纤苷进行治疗。